Literature DB >> 2166760

Peptides generated from C-reactive protein by a neutrophil membrane protease. Amino acid sequence and effects of peptides on neutrophil oxidative metabolism and chemotaxis.

E G Shephard1, R Anderson, O Rosen, M S Myer, M Fridkin, A F Strachan, F C De Beer.   

Abstract

We have recently provided evidence that C-reactive protein (CRP) could act as an up-regulatable substrate for membrane-associated neutrophil serine protease(s). The resultant degradation of CRP yielded small soluble bioactive peptides that inhibit many of the proinflammatory functions of activated neutrophils and could oppose the tissue destructive potential of these cells. We report on the reverse phase HPLC separation of the small TCA-soluble peptides obtained when CRP is degraded with nonstimulated or PMA-stimulated neutrophils and purified neutrophil membranes. The amino acid sequence of seven peptides isolated from the CRP digest has been ascertained and synthetic peptides homologous to these sequences have been synthesized. Three of the synthetic peptides corresponding to residues 201-206 (CRP-III), 83-90 (CRP-IV), and 77-82 (CRP-V) of the intact protein were identified to significantly inhibit superoxide production from activated neutrophils at 50 microM whereas CRP-III and CRP-V in addition inhibited neutrophil chemotaxis at this concentration. These peptides act additively and their action likely involves the signal transduction pathways for neutrophil activation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2166760

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  An Intrinsically Disordered Motif Mediates Diverse Actions of Monomeric C-reactive Protein.

Authors:  Hai-Yun Li; Jing Wang; Fan Meng; Zhe-Kun Jia; Yang Su; Qi-Feng Bai; Ling-Ling Lv; Fu-Rong Ma; Lawrence A Potempa; Yong-Bin Yan; Shang-Rong Ji; Yi Wu
Journal:  J Biol Chem       Date:  2016-02-23       Impact factor: 5.157

2.  Prevention of In vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein.

Authors:  C Zouki; M Beauchamp; C Baron; J G Filep
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

Review 3.  Regulation of C-reactive protein conformation in inflammation.

Authors:  ZhenYu Yao; Yanmin Zhang; HaiBin Wu
Journal:  Inflamm Res       Date:  2019-07-16       Impact factor: 4.575

4.  Structural and functional comparison of native pentameric, denatured monomeric and biotinylated C-reactive protein.

Authors:  Karolina E Taylor; Carmen W van den Berg
Journal:  Immunology       Date:  2006-12-08       Impact factor: 7.397

Review 5.  Regulation of Conformational Changes in C-reactive Protein Alters its Bioactivity.

Authors:  Naeem Ullah; Yi Wu
Journal:  Cell Biochem Biophys       Date:  2022-08-23       Impact factor: 2.989

6.  Characterization of neutrophil-mediated degradation of human C-reactive protein and identification of the protease.

Authors:  E G Shephard; S L Kelly; R Anderson; M Fridkin
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

7.  Therapeutic effects of a synthetic peptide of C-reactive protein in pre-clinical tumor models.

Authors:  B P Barna; D A Eppstein; M J Thomassen; J J Nestor; T Ho; S V Medendorp; S D Deodhar
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

8.  C-reactive protein (CRP) peptides inactivate enolase in human neutrophils leading to depletion of intracellular ATP and inhibition of superoxide generation.

Authors:  E G Shephard; R Anderson; O Rosen; M Fridkin
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

9.  The regulation of superoxide generation and nitric oxide synthesis by C-reactive protein.

Authors:  S Ratnam; S Mookerjea
Journal:  Immunology       Date:  1998-08       Impact factor: 7.397

Review 10.  A hypothesis resolving the apparently disparate activities of native and altered forms of human C-reactive protein.

Authors:  M J Shields
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.